All Interventions

    Acarbose

    Pharmaceuticals
    Metabolic Drugs

    Alpha-glucosidase inhibitor that slows carbohydrate absorption, extending lifespan in animal studies through caloric restriction mimicry.

    Evidence Summary

    6
    / 10Score
    Moderate
    Moderate Evidence

    Extends lifespan in mice (ITP program). Long safety history for diabetes. Mechanism aligns with caloric restriction and metabolic health. UPDATE (August 23, 2026): PREPRINT — NOT PEER-REVIEWED. A bioRxiv preprint (posted 24 June 2026) profiled male UM-HET3 mice treated from 4 to 12 months with rapamycin, acarbose, 17-alpha-estradiol, canagliflozin or caloric restriction, using untargeted metabolomics across seven tissues. A feature-stabilized XGBoost pipeline identified treated animals as recipients of a lifespan-extending intervention well before survival curves separate, and a leave-one-intervention-out procedure showed that models trained on any four interventions correctly classified mice receiving a fifth, unseen intervention — implying a partly shared metabolic signature across mechanistically distinct treatments. The dietary antioxidant ergothioneine rose consistently in brain, plasma and muscle, alongside common lipid remodelling. If this survives peer review it is a candidate short-horizon readout for geroprotector screening, and it is a notable hint that this drug does not act in complete metabolic isolation. It is explicitly NOT evidence that ergothioneine mediates the effect or that supplementing it reproduces any benefit — the association is correlative and untested causally, the cohort is male-only, and no human data exist. UPDATE (September 27, 2026): PEER-REVIEWED PERSPECTIVE, MOUSE DATA ONLY. Austad, Kaeberlein and Miller (Frontiers in Science, Sept 17 2026) synthesized NIA Interventions Testing Program data across all 14 agents now shown to extend mouse lifespan -- acarbose among them -- and proposed 12 candidate "aging rate indicators" (ARIs; adipose UCP1, cap-independent translation, MEK/ERK and MEK/p38 signaling, mTORC1 activity, adipose macrophage M1/M2 ratio, FNDC5, GPLD1, hippocampal BDNF/doublecortin) meant to give a faster readout of a slow-aging state than waiting years for survival curves to separate. This builds on the same ITP dataset referenced in the August 2026 metabolomics preprint above. It is a research roadmap, not new lifespan or human data: most ARI evidence comes from one lab's mouse stock, sex-specific effects were common across the underlying ITP hits (9 of 14 agents benefited males only), and no ARI has been validated in humans, non-human primates, or dogs. UPDATE (November 15, 2026): HUMAN CLINICAL EVIDENCE REFRESH. Acarbose's strongest human outcome data are in preventing, not reversing, dysglycemia. In the landmark STOP-NIDDM randomized trial (1,429 adults with impaired glucose tolerance; acarbose 100 mg three times daily; mean 3.3 years), progression to type 2 diabetes fell from 42% on placebo to 32% on acarbose — a 25% relative risk reduction (hazard ratio 0.75, 95% CI 0.63-0.90; Lancet 2002), and more acarbose-treated patients reverted to normal glucose tolerance. A secondary analysis reported fewer new cases of hypertension (34% relative reduction; HR 0.66, 0.49-0.89) and fewer major cardiovascular events (49% relative reduction; HR 0.51, 0.28-0.95; JAMA 2003), but these were secondary endpoints with wide confidence intervals. The larger, dedicated Acarbose Cardiovascular Evaluation (ACE) trial (6,522 Chinese adults with coronary heart disease and impaired glucose tolerance; acarbose 50 mg three times daily; median 5 years) confirmed an 18% lower incidence of diabetes (rate ratio 0.82, 0.71-0.94) but found NO reduction in major adverse cardiovascular events (HR 0.98, 0.86-1.11; Lancet Diabetes & Endocrinology 2017), tempering the earlier cardiovascular signal. A 2024 systematic review and meta-analysis of 101 randomized trials found acarbose significantly lowers fasting glucose, HbA1c, fasting insulin and HOMA-IR, with gastrointestinal effects (flatulence, loose stools) the main tolerability limit. Net: robust evidence that acarbose improves glycemic control and delays diabetes in impaired glucose tolerance; its longevity rationale in humans remains indirect, resting on improved metabolic health plus the animal lifespan data above. Educational information, not medical advice; acarbose is a prescription medicine, contraindicated in inflammatory bowel disease, intestinal obstruction and cirrhosis.

    Evidence Scale

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    AnecdotalStrong RCT

    Mechanism of Action

    Inhibits intestinal alpha-glucosidase enzymes, slowing carbohydrate digestion and absorption. Reduces postprandial glucose spikes. May mimic some CR effects.

    Who Is This For?

    Postprandial hyperglycemia, glucose optimization, longevity protocol component.

    Protocol & Dosing

    Dose

    25-100mg with meals. Start 25mg once daily.

    Frequency

    With carbohydrate meals

    Duration

    Ongoing

    Protocol Summary

    Oral with first bite of carbohydrate-containing meals. Titrate slowly for tolerance.

    Latest Evidence

    What the human trials actually show: diabetes prevention, not cardiovascular protection

    Acarbose's best human data are in people with impaired glucose tolerance. In the landmark STOP-NIDDM trial (1,429 adults, acarbose 100 mg three times daily, mean 3.3 years), progression to type 2 diabetes fell from 42% on placebo to 32% on acarbose — a 25% relative risk reduction — and more patients reverted to normal glucose tolerance. The larger, dedicated ACE cardiovascular outcomes trial (6,522 adults with coronary heart disease and impaired glucose tolerance, acarbose 50 mg three times daily, median 5 years) likewise cut new diabetes by 18%, but found no reduction in major cardiovascular events — tempering the striking but secondary cardiovascular signal from STOP-NIDDM. A 2024 meta-analysis of 101 randomized trials confirms acarbose meaningfully lowers fasting glucose, HbA1c, fasting insulin and insulin resistance.

    These are human trials in dysglycemia, not longevity outcomes: acarbose's lifespan data come from mice, and its healthspan rationale in people remains indirect. Gastrointestinal effects (flatulence, loose stools) are the main tolerability limit and improve with slow titration. Acarbose is a prescription medicine, contraindicated in inflammatory bowel disease, intestinal obstruction and cirrhosis. Educational information, not medical advice.

    Randomized controlled trials · relative risk reduction

    Acarbose and progression to type 2 diabetes

    Relative risk reduction vs placebo. The diabetes-prevention effect is consistent across STOP-NIDDM (impaired glucose tolerance; Lancet 2002) and the larger ACE trial (coronary heart disease + impaired glucose tolerance; Lancet Diabetes & Endocrinology 2017). The hypertension and cardiovascular signals are STOP-NIDDM secondary endpoints (JAMA 2003); the dedicated ACE cardiovascular outcomes trial found no reduction in major cardiovascular events (muted bar). Educational information, not medical advice.

    Key references: STOP-NIDDM: acarbose for prevention of type 2 diabetes — Lancet (2002) · STOP-NIDDM: cardiovascular disease & hypertension — JAMA (2003) · ACE trial: acarbose and cardiovascular/diabetes outcomes — Lancet Diabetes & Endocrinology (2017) · Acarbose on glycemic markers: meta-analysis of 101 RCTs — J Diabetes Metab Disord (2024)

    Interactions & Precautions

    Contraindications

    • Inflammatory bowel disease
    • Intestinal obstruction
    • Cirrhosis

    Potential Risks

    • •GI side effects
    • •Limited to carbohydrate meals

    Potential Side Effects

    Flatulence
    Bloating
    Diarrhea
    Abdominal pain

    Practitioner Notes

    Clinical annotations from Dr. Goel

    GI effects limit use but improve with time. Start very low. Most benefit with high-carb meals. Part of ITP-validated longevity stack.
    SG

    Dr. Sanjeev Goel

    Chief Medical Officer, Peak Human

    Cost & Access

    Cost Range

    $

    Accessibility

    Prescription

    Availability varies by location

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation